Arch Venture Fund Xii, L.P.
CIK 0001906837
Director10% Owner
Filings
15
Latest May 4, 2026
Issuers covered
5
Showing
15 of 15
Page 1
Track record
23 of 25 open-market trades scored (92% price coverage) - 2 issuers without price data. Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 23 | 57% | +0.6% | +2.4% | +23.4% | -22.8% |
| 90 days | 22 | 91% | +35.3% | +41.8% | +60.1% | -24.2% |
| 180 days | 22 | 27% | -8.5% | -11.3% | +26.8% | -45.0% |
| 365 days | 20 | 65% | +4.3% | +8.6% | +27.7% | -63.6% |
Issuers
Companies where Arch Venture Fund Xii, L.P. has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| NMRA | Neumora Therapeutics, Inc. | 9 | Oct 29, 2025 |
| MTSR | Metsera, Inc. | 2 | Nov 14, 2025 |
| PRME | Prime Medicine, Inc. | 2 | Aug 1, 2025 |
| RAPP | Rapport Therapeutics, Inc. | 1 | Jun 10, 2024 |
| SPTX | Seaport Therapeutics, Inc. | 1 | May 4, 2026 |
All filings
15 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|